[go: up one dir, main page]

SG10201906750XA - Assays for detecting the presence or amount of an anti-drug antibody - Google Patents

Assays for detecting the presence or amount of an anti-drug antibody

Info

Publication number
SG10201906750XA
SG10201906750XA SG10201906750XA SG10201906750XA SG10201906750XA SG 10201906750X A SG10201906750X A SG 10201906750XA SG 10201906750X A SG10201906750X A SG 10201906750XA SG 10201906750X A SG10201906750X A SG 10201906750XA SG 10201906750X A SG10201906750X A SG 10201906750XA
Authority
SG
Singapore
Prior art keywords
detecting
assays
amount
drug antibody
drug
Prior art date
Application number
SG10201906750XA
Inventor
Ryan Grabert
Susan Richards
Valerie Theobald
Yuanxin Xu
Jad Zoghbi
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201906750XA publication Critical patent/SG10201906750XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODY Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such 5 methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum. [Figure 1] 10
SG10201906750XA 2014-02-11 2015-02-11 Assays for detecting the presence or amount of an anti-drug antibody SG10201906750XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461938556P 2014-02-11 2014-02-11

Publications (1)

Publication Number Publication Date
SG10201906750XA true SG10201906750XA (en) 2019-09-27

Family

ID=52684652

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201906750XA SG10201906750XA (en) 2014-02-11 2015-02-11 Assays for detecting the presence or amount of an anti-drug antibody
SG11201606291VA SG11201606291VA (en) 2014-02-11 2015-02-11 Assays for detecting the presence or amount of an anti-drug antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606291VA SG11201606291VA (en) 2014-02-11 2015-02-11 Assays for detecting the presence or amount of an anti-drug antibody

Country Status (19)

Country Link
US (4) US9759732B2 (en)
EP (4) EP3422001B1 (en)
CN (1) CN106164670B (en)
AU (2) AU2015217261B2 (en)
CA (1) CA2939080A1 (en)
CY (1) CY1121341T1 (en)
DK (1) DK3105592T3 (en)
ES (1) ES2705403T3 (en)
HR (1) HRP20190026T1 (en)
HU (1) HUE041669T2 (en)
LT (1) LT3105592T (en)
MX (2) MX374652B (en)
PL (1) PL3105592T3 (en)
PT (1) PT3105592T (en)
RS (1) RS58212B1 (en)
SG (2) SG10201906750XA (en)
SI (1) SI3105592T1 (en)
TR (1) TR201900160T4 (en)
WO (1) WO2015123315A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3422001B1 (en) 2014-02-11 2020-03-25 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
EP2982987A1 (en) * 2014-08-08 2016-02-10 Proteomika, S.L. Lateral flow immunoassays for the detection of antibodies against biological drugs
US9927443B2 (en) * 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
CA3000929C (en) 2015-10-15 2023-09-19 Biocon Limited Method for detecting neutralizing antibodies against recombinant human insulin in human serum
CN108369227B (en) * 2015-12-16 2021-07-16 豪夫迈·罗氏有限公司 Three-step acid dissociation enzyme-linked immunosorbent assay (TADELIS)
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
EP3239711B1 (en) * 2016-04-27 2019-12-25 JIMRO Co., Ltd. Method for measuring anti-drug antibody
MX2019004691A (en) 2016-10-20 2019-12-09 I Mab Biopharma Us Ltd Novel cd47 monoclonal antibodies and uses thereof.
CN110997727B (en) * 2017-08-08 2025-03-18 豪夫迈·罗氏有限公司 Method for the determination of anti-drug antibodies in miniature pig samples
KR102551444B1 (en) * 2017-11-29 2023-07-06 에프. 호프만-라 로슈 아게 Anti-drug antibody assay with suppressed target interference
CN109358192B (en) * 2018-02-08 2020-05-12 中国科学院上海药物研究所 Device and method for removing free drugs in anti-drug antibody detection sample, preparation method and application of device
IL277890B2 (en) * 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
MX2021000331A (en) * 2018-07-10 2021-03-25 Regeneron Pharma METHODS TO MITIGATE THE INTERFERENCE OF THE PHARMACOLOGICAL TARGET IN AN IMMUNOASSAY OF ANTI-DRUG ANTIBODIES (ADA).
KR102718808B1 (en) * 2018-08-03 2024-10-16 브리스톨-마이어스 스큅 컴퍼니 Method for detecting anti-drug antibodies
CA3136161A1 (en) * 2019-04-16 2020-10-22 Laboratory Corporation Of America Holdings Methods and systems for detecting antibodies by surface plasmon resonance
KR102695013B1 (en) 2019-04-24 2024-08-13 삼성전자주식회사 Methods of manufacturing pellicle assembly and photomask assembly
CN111982615A (en) * 2019-05-23 2020-11-24 百奥泰生物制药股份有限公司 Dissociation liquid for dissociating drug/ADA compound and application thereof
CN112285351A (en) * 2019-07-22 2021-01-29 上海益诺思生物技术股份有限公司 ELISA detection method of anti-IgE monoclonal antibody
CA3148161A1 (en) * 2019-09-05 2021-03-11 Adverum Biotechnologies Anti-drug antibody assay
CN111171141A (en) * 2020-01-20 2020-05-19 苏州药明康德新药开发有限公司 Application of polyethylene glycol in preclinical safety evaluation
CN111024958B (en) * 2020-03-11 2020-06-23 同昕生物技术（北京）有限公司 Reagent for detecting monoclonal antibody drug and monoclonal antibody drug antibody and application thereof
CA3180569A1 (en) * 2020-05-01 2021-11-04 Regeneron Pharmaceuticals, Inc. Neutralizing antibody assay for therapeutic proteins
JP7478040B2 (en) * 2020-06-25 2024-05-02 シスメックス株式会社 METHOD FOR MEASURING Aβ PEPTIDE AND REAGENT COMPOSITION USED IN THE METHOD
CN116261662B (en) * 2020-10-14 2024-05-31 天境生物科技(上海)有限公司 Methods for reducing interference of therapeutic anti-CD 47 antibodies in pre-transfusion assays
JP7062803B1 (en) 2021-03-31 2022-05-06 積水メディカル株式会社 Anti-drug antibody measurement method
MX2024007473A (en) 2021-12-14 2024-09-10 Cdr Life Ag DUAL MHC-TARGETING T LYMPHOCYTE ACTIVATOR.
CN114047343B (en) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 Immunogenicity analysis kit of double-tolerance anti-IgE monoclonal antibody medicine and use method and application thereof
AU2023336565A1 (en) 2022-09-09 2025-02-20 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024064044A1 (en) * 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Neutralization antibody assay method
CN115561355B (en) * 2022-09-26 2024-04-30 重庆迪纳利医药科技有限责任公司 Method for detecting neutralizing antibody of carboxypeptidase G2 and detection system based on LC-MS/MS
CN116699147A (en) * 2023-08-04 2023-09-05 军科正源（北京）药物研究有限责任公司 Method for detecting total IgE content and related kit
CN117849327A (en) * 2024-03-06 2024-04-09 军科正源（北京）药物研究有限责任公司 Methods for detecting a secukinumab-resistant antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448632A1 (en) * 1988-12-09 1991-10-02 Centocor, Inc. Anti-idiotopic immunometric assay
US5187065A (en) * 1989-12-22 1993-02-16 Schutzer Steven E Method and materials for detecting lyme disease
US20090061466A1 (en) * 2006-03-09 2009-03-05 Wolfgang Hoesel Anti-drug antibody assay
MX2009012044A (en) * 2007-05-07 2009-11-18 Wyeth Corp Elimination of interference in immunoassays caused by anti-carbohydrate antibodies.
CA2712021A1 (en) * 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
JP2010078374A (en) 2008-09-24 2010-04-08 Olympus Corp Method of detecting anti-erythrocyte antibody
US7799532B2 (en) * 2008-11-12 2010-09-21 Hemopet Detection and measurement of thyroid hormone autoantibodies
KR20140008397A (en) 2011-02-17 2014-01-21 네스텍 소시에테아노님 Assays for detecting autoantibodies to anti-tnfa drugs
WO2013132000A1 (en) * 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes
BR112015032960B1 (en) * 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag immunoassay suppressed by interference to detect anti-drug antibodies in serum samples
EP3422001B1 (en) 2014-02-11 2020-03-25 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody

Also Published As

Publication number Publication date
US20150226758A1 (en) 2015-08-13
PL3105592T3 (en) 2019-04-30
CN106164670A (en) 2016-11-23
EP3667321B1 (en) 2022-07-27
EP4137816B1 (en) 2025-03-19
US20180088140A1 (en) 2018-03-29
AU2020264316A1 (en) 2020-11-26
RS58212B1 (en) 2019-03-29
HRP20190026T1 (en) 2019-02-22
CN106164670B (en) 2019-06-14
SI3105592T1 (en) 2019-02-28
EP3422001B1 (en) 2020-03-25
US11927596B2 (en) 2024-03-12
MX2020009021A (en) 2020-10-12
LT3105592T (en) 2019-01-25
HUE041669T2 (en) 2019-05-28
AU2015217261B2 (en) 2020-08-27
ES2705403T3 (en) 2019-03-25
EP3667321A1 (en) 2020-06-17
PT3105592T (en) 2019-01-23
US20220187327A1 (en) 2022-06-16
US20240288454A1 (en) 2024-08-29
MX2016010413A (en) 2016-11-30
US11215623B2 (en) 2022-01-04
CA2939080A1 (en) 2015-08-20
EP3105592B1 (en) 2018-10-17
US9759732B2 (en) 2017-09-12
EP3105592A1 (en) 2016-12-21
WO2015123315A1 (en) 2015-08-20
EP3422001A1 (en) 2019-01-02
MX374652B (en) 2025-03-06
CY1121341T1 (en) 2020-05-29
AU2015217261A1 (en) 2016-09-08
DK3105592T3 (en) 2019-02-04
EP4137816A1 (en) 2023-02-22
SG11201606291VA (en) 2016-08-30
TR201900160T4 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
PH12019501146A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
EP4464797A3 (en) Kit, device, and method for detecting lung cancer
PH12019501837A1 (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
MX2015012823A (en) Hcv antigen-antibody combination assay and methods and compositions for use therein.
EP3933406A3 (en) Antibodies to risperidone and use thereof
MA40390A (en) Assay methods involving dissociable nanoparticles
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
JOP20200216A1 (en) Assays to detect neurodegeneration
MX2016001573A (en) Assays for timp2 having improved performance in biological samples.
EP3721229A4 (en) Lateral flow assay and methods for detecting high concentration analytes
SA518391028B1 (en) Antibodies and assays for detection of cd37
MX2019000592A (en) Liquid analytical reagent dispensing apparatus and analytical kits and methods of use related thereto.
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
SG10201806729VA (en) Novel assay to detect human periostin
WO2014173546A3 (en) Platelet allo-antigen typing and platelet antibody tests
EP3207374A4 (en) Method and system for determining the concentration of an analyte in a fluid sample
MX2019000591A (en) Improved low sample volume urinalysis assay strip, analytical kits, and methods of use related thereto.
MX2021003484A (en) Methods for detecting hook effect(s) associated with anaylte(s) of interest during or resulting from the conductance of diagnostic assay(s).
SG10201901836PA (en) Test strip assembly
MX2018004322A (en) Method for detecting neutralizing antibodies against recombinant man insulin in man serum.
SG10201809158TA (en) Device and method for detecting blood group antigens by means of an incomplete antibody
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
MX2020005562A (en) ANTI-PD-L1 ANTIBODIES AND METHODS FOR USING THEM FOR THE DETECTION OF PD-L1.